Effect of AT-derived miRNA on the Biology and Insulin Sensitivity of Skeletal Muscle in Humans

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02459106

Acronym

miRNA

Enrollment

Registered

2015-06-01

Start date

2015-05-27

Completion date

2024-12-19

Last updated

2025-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Keywords

micro-RNA, insulin resistance

Brief summary

The purpose of this study is examine the effect of fat tissue-released miRNA on skeletal muscle and if abnormal fat tissue-released miRNA contributes to insulin resistance in obese individuals. This information will be important for our understanding of how the body's sugar metabolism is regulated and why people who are obese become insulin resistant and are more likely to develop type 2 diabetes.

Detailed description

Study Objectives: 1. To establish and optimize the methodology for measuring adipose tissue miRNA release. 2. To establish and optimize the methodology for measuring the effect of adipose tissue-released miRNA on skeletal muscle biology and insulin sensitivity. 3. To profile adipose tissue-released miRNA in lean insulin-sensitive and obese insulin-resistant healthy individuals. 4. To examine the effects of adipose tissue-released miRNA from lean insulin-sensitive individuals and obese insulin-resistant individuals on skeletal muscle biology and insulin sensitivity.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Able to communicate meaningfully with the investigator and legally competent to provide informed written consent * 18-65 years of age * BMI of 20-25 kg/m2 (lean subjects); 30-35 kg/m2 (obese subjects) * Stable body weight (\< 3 kg change in the last 8 weeks) * homeostatic model assessment (HOMA)-insulin resistance \<2.7 if lean; homeostatic model assessment (HOMA)-insulin resistance ≥2.7 if obese

Exclusion criteria

* Lactation or pregnancy, current and/or within last 6 months, per participant's report * Female subjects postmenopausal * Cardiovascular disease (unstable angina, myocardial infarction or coronary revascularization within 6 months) * Liver disease (AST or ALT(alanine aminotransferase)\>2.5 times the upper limit of normal) * Kidney disease (creatinine \>1.6 mg/dl) * Anemia (hemoglobin \<12 g/dl in men, \<11 g/dl in women) * Thyroid dysfunction (abnormal TSH) * HbA1c ≥6.5% * Uncontrolled hypertension (systolic BP\>160 mmHg, diastolic BP\>100 mmHg) * History of coagulopathies * History (within the last 5 years) or presence of malignancy, (skin cancers, with the exception of melanoma, may be acceptable) * Current or history of drug abuse or alcohol abuse (\>2 drinks/day) * Prior treatment (within last 3 months) with systemic glucocorticoids (\>2 weeks), beta-blockers, drugs for weight loss, niacin or fibrates * History of HIV, active Hepatitis B or C, or Tuberculosis (participant reported) * Smoke \> 5 cigarettes per day

Design outcomes

Primary

Measure	Time frame	Description
Levels of miRNA will be measured as well as the adipose tissue specific miRNA.	4 weeks	The effect of miRNA released by adipose tissue from lean insulin-sensitive and from obese insulin-resistant individuals on skeletal muscle biology and insulin signaling.

Countries

United States

Outcome results